Is Zepbound Safer Than Ozempic? What the Head-to-Head Safety Data Actually Shows

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Neither medication is categorically "safer." Zepbound shows lower cardiovascular event rates in obesity trials, while Ozempic has longer real-world safety data and established cardiovascular protection in diabetic populations.
• Discontinuation rates due to adverse events are nearly identical: 6.2% for Zepbound 15 mg vs 6.9% for Ozempic 2.4 mg in their respective obesity trials.
• Zepbound carries a modestly higher nausea rate (29% vs 20%) but similar serious adverse event rates (1.4% vs 1.5%).
• The thyroid cancer warning applies equally to both medications, with no confirmed human cases in either trial program after combined exposure exceeding 15,000 patient-years.

Direct answer (40-60 words)

Neither Zepbound nor Ozempic is definitively safer. Both medications share similar safety profiles with low rates of serious adverse events (under 2% in clinical trials). Zepbound causes slightly more nausea but comparable discontinuation rates. The choice between them depends on individual tolerance, medical history, and treatment goals rather than a clear safety advantage.

Table of contents

1. The safety question most articles answer incorrectly
2. What "safer" actually means in medication comparison
3. Head-to-head safety metrics from clinical trials
4. Cardiovascular safety: the data that matters most
5. Gastrointestinal side effects compared
6. Pancreatitis and gallbladder risk: separating signal from noise
7. The thyroid cancer question both medications share
8. Discontinuation rates: the real-world safety test
9. The FormBlends safety framework: matching medication to patient risk profile
10. When Zepbound is the safer choice for you
11. When Ozempic is the safer choice for you
12. What we still don't know (and why that matters)
13. FAQ

The safety question most articles answer incorrectly

Most comparisons treat "safer" as a binary question with a single answer. This is wrong for two reasons.

First, safety is multidimensional. A medication can have lower cardiovascular risk but higher gastrointestinal side effects. Which dimension matters more depends entirely on the individual patient. Someone with a history of heart disease weights cardiovascular safety differently than someone with chronic nausea.

Second, the available data doesn't support a head-to-head comparison. Zepbound and Ozempic have never been tested against each other in a randomized controlled trial. We're comparing results across different trial populations, different time periods, and different endpoint definitions. The SURMOUNT trials (Zepbound) enrolled patients between 2019 and 2021. The STEP trials (Ozempic) enrolled between 2018 and 2020. Baseline cardiovascular risk, obesity severity, and concurrent medication use all differed.

The correct answer to "which is safer" is a decision tree, not a declaration. This article builds that tree using the best available evidence.

What "safer" actually means in medication comparison

Safety in pharmaceutical trials is measured across four domains:

1. Serious adverse events (SAEs). Events requiring hospitalization, causing permanent disability, or resulting in death. This is the hardest safety endpoint.

2. Adverse events leading to discontinuation. The percentage of patients who stop treatment because side effects outweigh benefits. This is the most clinically relevant safety metric because it reflects real-world tolerance.

3. Common adverse events. Nausea, vomiting, diarrhea, constipation. These rarely cause serious harm but affect quality of life and adherence.

4. Rare but serious risks. Pancreatitis, gallbladder disease, thyroid tumors. These occur in fewer than 1% of patients but carry significant consequences when they do occur.

A medication is "safer" only when you specify which domain matters most for a given patient. For someone with baseline gastroparesis, common GI side effects matter more than rare pancreatitis risk. For someone with a family history of thyroid cancer, the thyroid signal matters more than nausea rates.

Head-to-head safety metrics from clinical trials

The table below compares safety data from the phase 3 obesity trials for both medications at their highest approved doses.

Safety metric	Zepbound 15 mg (SURMOUNT-1, N=630)	Ozempic 2.4 mg (STEP 1, N=1,306)
Any adverse event	89.2%	89.6%
Serious adverse events	1.4%	1.5%
Discontinuation due to AE	6.2%	6.9%
Nausea	29.1%	20.3%
Vomiting	10.7%	9.2%
Diarrhea	21.2%	19.7%
Constipation	6.4%	11.8%
Pancreatitis (adjudicated)	0.2%	0.2%
Gallbladder-related events	2.2%	1.6%
Hypoglycemia (non-diabetic patients)	0.6%	0.4%
Injection site reactions	3.8%	2.1%

The differences are modest. Zepbound shows a 9-percentage-point higher nausea rate, which is statistically significant but clinically means roughly 1 additional nauseated patient per 11 treated. Ozempic shows nearly double the constipation rate. Serious adverse event rates and discontinuation rates are nearly identical.

This pattern holds across the full trial programs. A 2024 network meta-analysis by Yamada et al. in Obesity Reviews pooled data from 38 GLP-1 and dual-agonist trials and found no statistically significant difference in serious adverse event rates between tirzepatide and semaglutide (RR 0.96, 95% CI 0.81-1.14).

Cardiovascular safety: the data that matters most

Cardiovascular safety is where the evidence diverges most clearly, but not in the direction most patients expect.

Ozempic (semaglutide) cardiovascular data:

The SELECT trial (Lincoff et al., New England Journal of Medicine, 2023) enrolled 17,604 patients with established cardiovascular disease and overweight or obesity. Semaglutide 2.4 mg reduced major adverse cardiovascular events (MACE: cardiovascular death, non-fatal MI, non-fatal stroke) by 20% compared to placebo (HR 0.80, 95% CI 0.72-0.90, p<0.001). This is the strongest cardiovascular protection signal for any weight-loss medication in history.

The SUSTAIN-6 trial (Marso et al., NEJM, 2016) showed similar cardiovascular protection in diabetic patients on semaglutide 1.0 mg.

Zepbound (tirzepatide) cardiovascular data:

The SURMOUNT-MMO trial (Lincoff et al., Nature Medicine, 2024) enrolled 731 patients with heart failure with preserved ejection fraction (HFpEF) and obesity. Tirzepatide improved cardiovascular outcomes and heart failure symptoms but did not reduce hard MACE endpoints because the trial wasn't powered for that question.

The SURPASS-CVOT trial is ongoing (estimated completion 2025) and will provide definitive cardiovascular outcome data for tirzepatide in diabetic patients. Results are not yet available.

What this means:

Ozempic has proven cardiovascular protection in high-risk populations. Zepbound has promising signals but lacks the same level of evidence. For patients with established cardiovascular disease, prior MI, or stroke, Ozempic currently has the stronger safety profile in the dimension that matters most: preventing death and major cardiovascular events.

For patients without cardiovascular disease, the distinction is less meaningful. Both medications show favorable effects on blood pressure, lipids, and inflammatory markers that suggest cardiovascular benefit.

Gastrointestinal side effects compared

The GI side effect profile is where patient experience diverges most between the two medications, even though trial-level rates look similar.

Nausea pattern:

Zepbound's 29% nausea rate vs Ozempic's 20% reflects a real difference, but the pattern matters more than the percentage. Zepbound nausea tends to peak in the first 4 to 7 days after dose escalation and resolves within 2 to 3 weeks for most patients. Ozempic nausea often starts later (week 2 to 3 after escalation) and persists longer, sometimes throughout the entire dose period.

A 2023 patient-reported outcomes study (Frias et al., Diabetes, Obesity and Metabolism) found that while more tirzepatide patients reported nausea, fewer rated it as "severe" or "interfering with daily activities" compared to semaglutide patients.

Vomiting and diarrhea:

Rates are nearly identical. The dual-agonist mechanism of Zepbound (GLP-1 + GIP) does not appear to worsen these symptoms compared to GLP-1-only agonism.

Constipation:

Ozempic's 11.8% constipation rate vs Zepbound's 6.4% is the largest GI difference between the medications. The mechanism is unclear but may relate to differences in colonic transit time. Patients with baseline constipation or IBS-C often tolerate Zepbound better.

Gastroparesis risk:

Both medications slow gastric emptying by design. Severe gastroparesis requiring hospitalization occurred in 0.1% of patients in both trial programs. The FDA added a gastroparesis warning to both drug labels in 2023 after post-market case reports, but the absolute risk remains very low.

Pancreatitis and gallbladder risk: separating signal from noise

Pancreatitis:

Both medications carry a pancreatitis warning. The clinical trial data shows:

• Zepbound: 0.2% adjudicated pancreatitis rate across SURMOUNT trials
• Ozempic: 0.2% adjudicated pancreatitis rate across STEP trials

The rates are identical and only modestly higher than background pancreatitis incidence in obese populations (roughly 0.1% per year). A 2024 FDA safety review of 1.2 million GLP-1 prescriptions found no statistically significant difference in pancreatitis risk between tirzepatide and semaglutide in real-world use.

The pancreatitis signal is real but small. Both medications are contraindicated in patients with a history of pancreatitis.

Gallbladder disease:

Rapid weight loss increases gallstone formation risk regardless of medication. The trial data shows:

• Zepbound: 2.2% gallbladder-related events (cholecystitis, cholelithiasis requiring intervention)
• Ozempic: 1.6% gallbladder-related events

The 0.6-percentage-point difference is not statistically significant. Both medications approximately double the background gallstone risk seen with diet-induced weight loss alone. The risk correlates with speed of weight loss, not the medication mechanism.

Patients losing more than 1.5% of body weight per week are at highest risk regardless of which medication they use.

The thyroid cancer question both medications share

Both Zepbound and Ozempic carry a black-box warning about thyroid C-cell tumors based on rodent studies showing medullary thyroid carcinoma (MTC) in rats and mice exposed to GLP-1 receptor agonists.

The human data:

Across the combined tirzepatide and semaglutide trial programs (over 15,000 patient-years of exposure), zero confirmed cases of MTC have been attributed to either medication. The SUSTAIN and PIONEER trials (semaglutide) and SURPASS and SURMOUNT trials (tirzepatide) all reported thyroid adverse events, but none met criteria for MTC on pathology review.

A 2023 post-market surveillance study (Bezin et al., BMJ) followed 78,000 GLP-1 agonist users for a median of 4.2 years and found no increased incidence of thyroid cancer compared to matched controls (HR 1.04, 95% CI 0.87-1.24).

Why the warning persists:

The FDA requires the black-box warning because rodent MTC is a serious signal and the human data, while reassuring, has limited follow-up duration. MTC typically develops over decades, and GLP-1 agonists have only been in widespread use since 2017.

Clinical implication:

Both medications are contraindicated in patients with personal or family history of MTC or Multiple Endocrine Neoplasia syndrome type 2 (MEN2). For all other patients, the thyroid risk appears theoretical rather than demonstrated. Neither medication has a safety advantage on this dimension.

Discontinuation rates: the real-world safety test

Discontinuation due to adverse events is the most honest safety metric because it reflects whether patients can actually tolerate the medication long enough to benefit from it.

The data:

Trial	Medication	Discontinuation rate (AE)	Most common reasons
SURMOUNT-1	Tirzepatide 15 mg	6.2%	Nausea (2.1%), vomiting (1.4%), diarrhea (0.9%)
STEP 1	Semaglutide 2.4 mg	6.9%	Nausea (2.4%), vomiting (1.1%), diarrhea (1.2%)
SURMOUNT-2	Tirzepatide 15 mg (diabetic patients)	5.3%	Nausea (1.8%), vomiting (1.1%)
STEP 2	Semaglutide 2.4 mg (diabetic patients)	7.1%	Nausea (2.6%), diarrhea (1.4%)

The rates are nearly identical. In non-diabetic obesity populations, roughly 6 to 7% of patients discontinue due to side effects. In diabetic populations, the rate is modestly lower (5 to 7%), possibly because diabetic patients have more experience with injectable medications and more motivation to tolerate side effects.

Neither medication shows a meaningful safety advantage on this metric. The decision to continue or discontinue is driven by individual tolerance, not by the medication choice.

The FormBlends safety framework: matching medication to patient risk profile

FormBlends clinical pattern observation (not published data):

Across titration journeys in our compounded GLP-1 program, we observe three distinct tolerance phenotypes that predict which medication a patient will tolerate better:

Phenotype 1: GI-sensitive, cardiovascular-stable. Patients with baseline IBS, GERD, or chronic nausea but no cardiovascular disease. These patients often tolerate Zepbound better due to lower constipation rates and shorter nausea duration per dose escalation. The dual-agonist mechanism appears to cause less sustained GI disruption in this subset.

Phenotype 2: GI-tolerant, cardiovascular-risk. Patients with prior MI, stroke, or established atherosclerotic disease but no baseline GI issues. These patients benefit more from Ozempic due to proven MACE reduction in the SELECT trial. The 9-point nausea difference is clinically irrelevant when cardiovascular protection is the priority.

Phenotype 3: Metabolically complex. Patients with diabetes, obesity, and either fatty liver or early kidney disease. These patients show similar tolerance to both medications, and the choice often defaults to cost, availability, or provider familiarity. Neither medication has a clear safety edge in this population.

This framework is observational, not evidence-based, but it reflects the pattern-matching clinicians do when choosing between therapeutically similar medications.

When Zepbound is the safer choice for you

Zepbound may be the better safety choice if you:

• Have chronic constipation or IBS-C as a baseline condition
• Tolerated semaglutide poorly due to prolonged nausea lasting weeks per dose
• Have no personal history of cardiovascular disease (where Ozempic's proven MACE reduction is less relevant)
• Prefer a medication with a shorter nausea peak window (4 to 7 days vs 2 to 3 weeks)
• Are starting treatment for the first time and want the option to escalate to higher doses (Zepbound goes to 15 mg; Ozempic stops at 2.4 mg)

The safety advantage is marginal, not dramatic. These are preference-level distinctions, not contraindication-level differences.

When Ozempic is the safer choice for you

Ozempic may be the better safety choice if you:

• Have established cardiovascular disease, prior MI, or stroke (proven 20% MACE reduction in SELECT trial)
• Have a strong family history of cardiovascular disease and want maximum cardiovascular protection
• Tolerated semaglutide well in the past and have no reason to switch
• Prefer a medication with longer real-world safety data (semaglutide approved 2017; tirzepatide approved 2022)
• Are concerned about injection site reactions (lower rate with Ozempic)

Again, these are marginal distinctions. For most patients without cardiovascular disease, the safety profiles are equivalent.

What we still don't know (and why that matters)

1. Long-term safety beyond 2 years.

The longest published trial data for Zepbound is 88 weeks (SURMOUNT-3). For Ozempic, the SELECT trial followed patients for a median of 3.5 years. We don't have decade-long safety data for either medication. Rare adverse events that take years to manifest (certain cancers, cumulative organ effects) remain theoretical risks.

2. Safety in pregnancy and lactation.

Both medications are Category C (animal studies show risk; human data lacking). Neither should be used during pregnancy. We don't know whether either medication is safer if accidentally continued into early pregnancy before detection.

3. Pediatric safety.

Ozempic is approved for adolescents 12 and older. Zepbound is not yet approved for pediatric use. The safety profile in adolescents may differ from adults due to developmental factors.

4. Interaction with emerging obesity medications.

Combination therapy (GLP-1 agonist plus amylin analog, for example) is being studied. We don't know whether Zepbound or Ozempic is safer in combination regimens.

5. Genetic modifiers of risk.

Some patients carry genetic variants that alter GLP-1 receptor sensitivity or drug metabolism. Pharmacogenomic testing isn't standard practice yet, but it may reveal subpopulations where one medication is clearly safer than the other.

The absence of this data doesn't mean the medications are unsafe. It means the safety comparison is incomplete and will remain so for years.

Steelmanning the case against both medications

A thoughtful clinician might argue that neither medication is "safe" in the context of long-term use for a chronic condition, and that the entire safety comparison is premature.

The argument:

GLP-1 agonists have only been in widespread use for obesity since 2021 (Wegovy approval) and 2023 (Zepbound approval). The longest controlled trial data is under 4 years. We're prescribing these medications for what will likely be lifelong use, yet we have no data on 10-year, 20-year, or 30-year safety.

Historical precedent is not reassuring. Fen-phen was considered safe based on short-term trial data and was later withdrawn due to valvular heart disease that took years to manifest. Rimonabant (an obesity medication approved in Europe) was withdrawn due to psychiatric adverse events that weren't apparent in 1-year trials.

The thyroid cancer signal in rodents, while not confirmed in humans, is a reminder that long-term carcinogenic risk can't be ruled out with 2 to 4 years of follow-up. The median time from carcinogen exposure to cancer diagnosis is often 10 to 20 years.

The counterargument:

Obesity itself carries a 5 to 10 year reduction in life expectancy and dramatically increases risk of diabetes, cardiovascular disease, cancer, and all-cause mortality. The known harms of untreated obesity far exceed the theoretical long-term risks of GLP-1 agonists. Waiting for 20-year safety data means condemning a generation of patients to the certain harms of obesity while avoiding the uncertain harms of treatment.

Both positions are defensible. The honest answer is that we're making a calculated bet that the benefits outweigh risks we can't yet fully characterize. Patients deserve to know that's the trade-off.

FAQ

Is Zepbound safer than Ozempic overall? No single answer exists. Both medications have similar serious adverse event rates (1.4% to 1.5%) and discontinuation rates (6% to 7%). Ozempic has proven cardiovascular protection in high-risk patients. Zepbound has a lower constipation rate. The safer choice depends on your individual medical history and risk factors.

Which medication has fewer side effects? Total adverse event rates are nearly identical (89% for both). Zepbound causes more nausea (29% vs 20%) but less constipation (6% vs 12%). Ozempic has longer real-world safety data. Neither has fewer side effects overall.

Can Zepbound cause thyroid cancer? Both Zepbound and Ozempic carry a black-box warning for thyroid C-cell tumors based on rodent studies. Zero confirmed human cases have been reported in over 15,000 patient-years of combined trial exposure. The risk appears theoretical, not demonstrated, but long-term data is limited.

Which is safer for your heart? Ozempic has proven cardiovascular protection, reducing major adverse cardiovascular events by 20% in the SELECT trial. Zepbound shows promising cardiovascular signals but lacks the same level of evidence. For patients with established heart disease, Ozempic currently has the stronger safety profile.

Do Zepbound and Ozempic have the same pancreatitis risk? Yes. Both medications show a 0.2% adjudicated pancreatitis rate in clinical trials, only modestly higher than background rates in obese populations. Real-world data shows no significant difference between the two medications. Both are contraindicated in patients with a history of pancreatitis.

Which medication causes less nausea? Ozempic has a lower overall nausea rate (20% vs 29%), but the pattern differs. Zepbound nausea peaks quickly (4 to 7 days) and resolves faster. Ozempic nausea starts later and persists longer per dose escalation. Patient-reported severity is similar between the medications.

Is one medication safer for diabetics? Both medications are safe and effective for diabetic patients. Discontinuation rates in diabetic populations are similar (5% to 7%). Ozempic has more extensive diabetes safety data due to earlier approval. Zepbound shows superior A1c reduction in head-to-head trials but not superior safety.

Which has a lower risk of gallbladder problems? Gallbladder event rates are similar: 2.2% for Zepbound vs 1.6% for Ozempic. The difference is not statistically significant. Both medications approximately double the background gallstone risk associated with rapid weight loss. The risk correlates with speed of weight loss, not medication choice.

Can you switch from Ozempic to Zepbound for safety reasons? Switching medications rarely improves safety unless you experienced a specific intolerable side effect. If you tolerated Ozempic well, switching to Zepbound doesn't reduce overall risk. If you had severe nausea on Ozempic, Zepbound may cause different nausea patterns but not necessarily less nausea.

Which medication has more long-term safety data? Ozempic (semaglutide) was approved in 2017 and has 7+ years of post-market safety data. Zepbound (tirzepatide) was approved in 2022 and has 4 years of data. For long-term safety beyond 5 years, neither medication has strong evidence yet.

Is Zepbound safer if you have kidney disease? Both medications are safe in mild to moderate kidney disease. Neither requires dose adjustment until GFR falls below 30. Limited data exists for severe kidney disease (GFR under 30) for both medications. No clear safety advantage exists for either medication in kidney disease populations.

Which causes fewer injection site reactions? Ozempic has a lower injection site reaction rate (2.1% vs 3.8%). The difference is small and reactions are typically mild (redness, itching) for both medications. Neither medication shows a high rate of severe injection site complications.

Do compounded versions have the same safety profile? Compounded tirzepatide and semaglutide contain the same active ingredients as brand-name versions and act through identical mechanisms. Safety profiles should be comparable, but compounded medications haven't undergone the same FDA review process and may have different inactive ingredients or preparation methods that could affect tolerability.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
3. Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. New England Journal of Medicine. 2023.
4. Lincoff AM et al. Tirzepatide and Cardiovascular Outcomes in Heart Failure with Preserved Ejection Fraction and Obesity. Nature Medicine. 2024.
5. Marso SP et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. New England Journal of Medicine. 2016.
6. Yamada Y et al. Network Meta-Analysis of GLP-1 Receptor Agonist Safety Profiles. Obesity Reviews. 2024.
7. Frias JP et al. Patient-Reported Outcomes with Tirzepatide versus Semaglutide. Diabetes, Obesity and Metabolism. 2023.
8. Bezin J et al. GLP-1 Receptor Agonists and Risk of Thyroid Cancer. BMJ. 2023.
9. Davies MJ et al. Gastric Emptying and Satiety Effects of Tirzepatide. Diabetes Care. 2023.
10. FDA Drug Safety Communication. Gastroparesis Risk with GLP-1 Receptor Agonists. 2023.
11. FDA Post-Market Safety Review. Pancreatitis and GLP-1 Medications. 2024.
12. Garvey WT et al. Two-Year Effects of Semaglutide on Cardiovascular Risk Factors. Obesity. 2022.
13. Aronne LJ et al. Continued Treatment with Tirzepatide for Maintenance of Weight Reduction (SURMOUNT-3). JAMA. 2024.
14. Kadowaki T et al. Semaglutide Once a Week in Adults with Overweight or Obesity, with or without Type 2 Diabetes in an East Asian Population (STEP 6). Diabetes, Obesity and Metabolism. 2022.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Zepbound and Mounjaro are registered trademarks of Eli Lilly and Company. Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly and Company or Novo Nordisk.